Background: Penicillins and cephalosporins are among the most widely used and successful antibiotics. The emergence of resistance to these L-lactams, most often through bacterial expression of L-lactamases, threatens public health. To understand how L-lactamases recognize their substrates, it would be helpful to know their binding energies. Unfortunately, these have been difficult to measure because L-lactams form covalent adducts with L-lactamases. This has complicated functional analyses and inhibitor design.
Introduction
L-Lactamases catalyze the hydrolysis of L-lactam antibiotics, such as penicillins and cephalosporins, and are the most widespread bacterial resistance mechanism to these drugs [1] . Partly in response to the emergence and spread of L-lactamases, many L-lactam derivatives have been developed; over 40 are currently used in clinical practice. These analogs preserve the L-lactam core of the drug but explore diverse functionality o¡ the C6(7) position of the penicillin/cephalosporin ring, in what we will refer to as the R1 side chain (Fig. 1) . The di¡erent R1 side chains confer di¡erent pharmacological pro¢les, di¡erent bacterial spectra of action, and di¡erent levels of resistance to L-lactamases. Whereas early penicillins and cephalosporins, such as penicillin G and cephalothin ( Fig. 1) , are rapidly inactivated by L-lactamases, later agents, such as cloxacillin and ceftazidime, are relatively inert to, or indeed inhibit, these enzymes. Despite intense study, it has been di¤-cult to understand how these seemingly de¢ning R1 side chains contribute to L-lactam^L-lactamase recognition.
The problem lies in the covalent bond that L-lactams form with Group I and Group II L-lactamases. In these enzymes, the catalytic serine attacks the lactam bond to form an acyl-adduct (Fig. 2) ; this step is rapid for L-lactamases. The acyl-adduct is then hydrolyzed in a second step; deacylation is rate determining for Group I L-lac- tamases and for poor substrates and inhibitors of both classes of enzyme. The covalent nature of the acyl-adduct, and its rapid formation, means that binding is e¡ectively irreversible; binding equilibria are not readily available through steady state kinetics [2] . This precludes easy energetic analyses, which assume reversible equilibria. In L-lactamases, K m values are convolutions of irreversible acylation and deacylation rates with reversible on and o¡ rates, and IC 50 values are often dominated by rates of deacylation. Rarely do they re£ect binding energies or inhibitor^enzyme complementarity in any simple way [3, 4] . Indeed, both structural [5, 6] and stability [7] studies have suggested that some L-lactam inhibitors of L-lactamases ¢t the enzyme poorly^their inhibitory properties derive entirely from their ability to form an acyl-adduct and then block attack by the hydrolytic water. On the other hand, some R1 side chains undoubtedly ¢t the enzymes well. Identifying, far less quantifying, which ones do so has been di¤cult.
To investigate the energetic bases of L-lactam functional group recognition by L-lactamases, we have synthesized acylglycineboronic acids that bear the R1 side chains of eight characteristic penicillins and cephalosporins (Fig. 1) . Boronic acids are transition-state analog inhibitors of Group I and Group II L-lactamases [8^14] (Fig. 3) . Unlike L-lactams, they form reversible adducts with these enzymes; binding energies thus can be calculated directly from K i values. By comparing the a¤nities of di¡erent acylglycineboronic acids, we can determine what the different R1 side chains contribute to binding to a L-lactamase. By comparing the a¤nities to a Group I L-lactamase, AmpC, and a Group II L-lactamase, TEM-1, we can investigate di¡erential recognition between characteristic representatives of the two most widespread classes of L-lactamases. To give the binding energies a molecular context, we have determined the structures of two of these inhibitors in their complexes with AmpC L-lactamase by X-ray crystallography. Comparing one of these structures with that of its L-lactam counterpart in complex with AmpC [6] allows us to investigate how interactions with the R1 side chain di¡er between the acylated ground state and the presumptive deacylation high-energy intermediate. To explore the application of acylglycineboronic acids to reversing L-lactamase-mediated resistance at the level of cell culture, we have investigated their ability to act synergistically with L-lactams against resistant, pathogenic bacteria.
Results

Synthesis
Six acylglycineboronic acids (6, 7, 8, 9, 10, 11, 12) were synthesized through nitrogen displacement with LiN[Si(CH 3 ) 3 ] 2 on chloromethylboronic acid pinacol ester 1, followed by deprotection with equimolar methanol, and ¢nally condensation with an acylchloride. The yield of these two-step syntheses varied from 62 to 92%. Slight changes to this general scheme were performed to synthesize 5, 13, and 15. Deprotection of 4 was performed with acetic acid; reaction with acetic anhydride gave 5 in 60% yield. The condensation of compound 12 with 4-mercaptopyridine gave 13 in 90% yield. Compound 14 was obtained by preactivating (Z)-2-amino-K-[1-(tert-butoxycarbonyl)-1-methylethoxyimino]-4-thiazoleacetic acid as a mixed anhydride followed by reaction with the deprotected 4. The tert-butoxycarbonyl group of 14 was removed with TFA to give 15 in 64% yield over three steps. This general synthetic scheme seems well suited to attaching the R1 side chains of L-lactams to glycineboronic acids.
Binding constants
The di¡erential a¤nities of the acylglycineboronic acids allowed us to determine the contributions of the R1 side chain of L-lactams to molecular recognition by the various enzymes. Against the Group I L-lactamase AmpC, the K i values spanned a 1000-fold range, from 20 nM to 19 WM (Table 1) . Comparing the minimal amide side chain of 3 (K i 4.8 WM) to methylboronic acid (K i 1 mM) or to boric acid (K i 2.8 mM) suggests that the amide group itself contributes 3.2 kcal/mol to binding in this series (using vvG bind = 3RTlnK 1 /K 2 ). Comparing the a¤nity of 3 to compounds with more elaborate side chains, such as the ceftazidime analog 15 (K i 20 nM), suggests that variations distal to the amide group can contribute at least 4.0 kcal/ mol further to the interaction energy with AmpC.
The acylglycineboronic acids bound less tightly to the Group II L-lactamase TEM-1 than they did to AmpC (Table 1 ). Against TEM-1, K i values varied from 0.39 to 162 WM. These values were 8^40-fold worse (higher) than with AmpC. As with AmpC, compound 15, bearing the ceftazidime side chain, was the most active compound against TEM-1 (K i 0.39 WM). Fig. 4 . Stereoview of 2Fo3Fc electron density of the re¢ned models for AmpC complexes of (A) compound 9 and (B) compound 11. The density is contoured at 1 s. Carbon atoms are colored orange, oxygen atoms red, nitrogen atoms blue, sulfur atoms green, chlorine atoms magenta, and boron atoms purple. These ¢gures were generated using Turbo [38] .
Selectivity testing
Compound 3, bearing the minimal amide side chain, and compound 15, bearing the relatively elaborate ceftazidime side chain, were tested for L-lactamase selectivity versus the serine proteases K-chymotrypsin, L-trypsin, and elastase (Table 2) . Compound 3 showed no activity up to 100 WM against any of the proteases. Compound 15 had an IC 50 of 82 nM for AmpC and a projected IC 50 of 2 mM for K-chymotrypsin, 450 WM for elastase, and no measurable activity against L-trypsin. These assays were performed at a similar ratio of substrate concentration to K m for each enzyme.
X-ray crystallographic structure determination
The structures of both 9 and 11 in complex with the Group I L-lactamase AmpC were determined to 1.75 A î and 1.90 A î resolution, respectively ( Table 3 ). The location of the inhibitor in each complex was unambiguously identi¢ed in the initial Fo3Fc di¡erence maps when contoured at a level of 3 c. Simulated annealing omit maps of the re¢ned models agree well with the placement of the inhibitors in the active sites (not shown).
The quality of each of the models was analyzed with the program Procheck [15] . For the model of the complex of 9 with AmpC, 92.9% of the non-proline, non-glycine resi- Table 4 Interactions in complexed and native AmpC L-lactamase a Distances are for monomer 1 of the asymmetric unit. Monomer 1 was chosen because electron density for the inhibitors was better and average B-factors for the inhibitor atoms were 3^8 A î 2 lower in monomer 1 versus monomer 2; the respective distances di¡er only slightly between the two monomers. The RMSD for the CK atoms of the two monomers is 0.22 A î for 9/AmpC and 0.23 A î for 11/AmpC. The RMSD for the inhibitor atoms between the two molecules is 0.204 A î for 9/AmpC and 0.271 A î for 11/AmpC when the CK atoms are overlaid.
b Distances are for monomer 2 of the asymmetric unit.
c Not present. d In the native structure, Wat402 is called Wat387.
dues were in the most favored region of the Ramachandran plot (7.1% in the additionally allowed region), and for the complex of 11 with AmpC, 91.9% of the non-proline, non-glycine residues were in the most favored region (8.1% in the additionally allowed region). The structures have been deposited with the PDB as 1FSY (complex with 9) and 1FSW (complex with 11).
In both structures electron density is observed connecting OQ of the catalytic Ser64 to the boron atom of the inhibitors (Fig. 4) . The geometry around the boron is tetrahedral, as expected. The O1 of the boronic acid is within good hydrogen-bonding distance of the backbone nitrogens of Ser64 and Ala318 and also the backbone oxygen of Ala318 (Table 4 ). These interactions are highly conserved in L-lactamase structures with transition-state analogs [10,12^14,16] . The O2 of the boronic acid, which probably represents the position of the deacylating water in the high-energy intermediate [6, 13] , hydrogen bonds with the putative catalytic base Tyr150 [16, 17] (Table 4) . Two well-ordered water molecules are also observed in the region of the tetrahedral center of each complex, as seen in a previous structure of AmpC in complex with a boronic acid inhibitor [13] . The ¢rst water (Wat402) interacts with O2 of the boronic acid, OQ1 of Thr316, and another water molecule (Wat506). The second water (Wat403) interacts with Wat402, as well as with ON1 of Asn346 and NR1 of Arg349. In the complex with 9, Wat403 is also within hydrogen bonding distance to another water molecule (Wat549) ( Table 4 ).
In the crystal structures, the amide groups in the acylglycineboronic acids are placed close to where the analogous R1 side chain amide is placed in the structures of complexes between L-lactams and L-lactamases [6, 18, 19] . The amide groups in both the transition-state analog structures and the L-lactam acyl-adducts make similar interactions with the enzymes. In the structure of 11 with AmpC, the carbonyl oxygen (O6) of the amide group interacts with NN2 of Asn152 (2.8 A î ) and NO2 of Gln120 (2.9 A î ) ( Table 4) ; both residues are completely conserved among Group I L-lactamases. In the complex of 9 with AmpC, only the interaction between NN2 of Asn152 and O6 is seen (2.5 A î ). Gln120 appears unable to hydrogen bond with O6 due to a steric con£ict that would occur with the chlorine atom of the inhibitor; instead, this residue has rotated by 119³ around M 2 , away from the chlorine atom. In the complex with 9, an interaction is also observed between Ala318O and N4 (3.3 A î ) ( Table 4) .
The unique part of the R1 side chain of compound 11, the thiophene ring, appears to make few interactions with AmpC. Di¡erence density suggests that this ring can assume two conformations, which di¡er from each other by a 180³ rotation around the C7^C8 bond. In each of the conformations, the atoms to which the thiophene is nearest are Thr319C and Asn343NN2; the distances are between 3.4 and 3.5 A î . The nearest atom to the sulfur of the thiophene ring in one conformation is the CL of Ala318 (3.7 A î ); there is also a water molecule (Wat745) 3.4 A î away from the sulfur in this conformation. In the Table 4 . These ¢gures were generated with MidasPlus [39] .
second conformation, the sulfur is nearest to NO2 of Gln120 (4.3 A î ) and is close to two water molecules (Wat744, 3.8 A î and Wat743, 3.9 A î ).
In the complex of 9 with AmpC, O10 of the isoxazole ring interacts with a water molecule (Wat569, 3.1 A î ). The exocyclic methyl group (C9) packs against the aryl ring of Tyr221. The chlorobenzyl ring of the inhibitor is located in a hydrophobic pocket formed by residues Leu119 and Leu293. The CL of Ala318 also contributes to burial of this ring. The distances range from 3.6 A î (from C18 to CL of Ala318) to 4.3 A î (from C15 to CN2 of Leu119 and to CN1 of Leu293). This ring is also near residues Asn289 and Asn343 and appears to make van der Waals interactions with these residues. As mentioned above, the chlorine atom is placed near Gln120 (3.8 A î ).
Microbiology
The minimum inhibitory concentration (MIC) of ceftazidime and cefotaxime against the EB5 strain of Enterobacter cloacae, which does not produce a Group I L-lactamase, were 0.4 Wg/ml and 0.25 Wg/ml, respectively. Administered alone, neither 10 nor 15 had measurable activity; additionally there was no synergy observed against this strain when these compounds were administered with either ceftazidime or cefotaxime. Similarly, compound 15 had no activity by itself against Staphylococcus aureus strain V41; the MIC of compound 10 alone was 128 Wg/ml against this strain. Against strain 265A of E. cloacae, which hyper-produces a Group I L-lactamase, the MIC values of ceftazidime and cefotaxime rose to 256 and 128 Wg/ml, respectively. Both compounds 10 and 15 showed synergy with these L-lactams against this strain. Compound 15 reduced the MIC of ceftazidime by 256-fold at 32 Wg/ml of the inhibitor (data not shown) and reduced the MIC of cefotaxime by 128-fold at the same concentration (Table 5 ). Both inhibitors also showed synergy with amoxicillin against S. aureus expressing a Group II L-lactamase (Table 5) .
Disk di¡usion plate assays were performed to study the e¡ects of compounds 10 and 15 on the e¤cacy of the L-lactam ceftazidime. As expected, the plate containing E. cloacae that does not produce a L-lactamase shows a large inhibition halo surrounding the upper disks that contain ceftazidime. The lower disks, which contain compound 10 (right) or 15 (left), have no e¡ect on the inhibition halo of ceftazidime, nor do they show any inhibition halos of their own (Fig. 6A) . The plate containing E. cloacae that hyper-produce a Group I L-lactamase shows greatly reduced inhibition halos surrounding the upper disks containing ceftazidime, and in contrast to the pre- vious plate, the inhibition halos in the regions between the two disks are substantially increased (Fig. 6B ). This increase in the size of the inhibition halos between the two disks indicates that each compound has a synergistic e¡ect when coupled with ceftazidime.
Discussion
The acylglycineboronic acids span ¢ve orders of magnitude in a¤nity for AmpC, from a dissociation constant of 2.8 mM for boric acid itself to 20 nM for the ceftazidime analog 15 (Table 1 ). This suggests that the R1 side chains of L-lactams can make considerable contributions to a¤n-ity for L-lactamases. The result is unexpected, if only because the e¡ect of R1 side chains on a¤nity has previously been largely unknown. The compounds appear to be selective for L-lactamases, especially Group I L-lactamases resembling AmpC, showing little a¤nity for serine proteases that are known to be inhibited by peptide boronic acids [20] (Table 2 ). This is consistent with the speci¢c recognition of the R1 side chains by serine L-lactamases. The di¡erential energies between compounds allow us to interpret the interactions that we observe in the crystal structures of two of these inhibitors, and by analogy, those observed in other L-lactam complexes. Additionally, comparing the X-ray crystal structure of a transition-state analog complex with that of an acyl-enzyme intermediate suggests how recognition of the R1 side chain changes between the transition state and the acylated ground state in Group I L-lactamases.
An important contribution to a¤nity comes from the amide group common to all the inhibitors. Comparing compound 3 to methylboronic acid suggests that this amide contributes 3.2 kcal/mol to the free energy of binding. This group represents the C6(7) R1 amide that is ubiquitous among L-lactam antibiotics (Fig. 1) . In previous structures with L-lactams, the amide oxygen of the side chain has been observed to hydrogen bond to the side chain of the conserved Asn152 (Asn132 in Group II L-lactamases). The amide nitrogen of the R1 side chain has been observed to hydrogen bond to the main chain carbonyl of residue 318 in Group I L-lactamases (residue 237 in Group II L-lactamases) [6, 16, 18, 19, 21] . In the X-ray crystal structures of 9 and 11 in complex with AmpC, the R1 amide hydrogen bonds to Asn152 (Fig. 5 , Table 4 ). The hydrogen bonding interaction with Ala318 is observed in the structure of AmpC with 9 but not with 11. The hydrogen bond between the ligand amide nitrogen and the backbone carbonyl of residue 318/237 may not be as well conserved structurally as that of Asn152/Asn132 with the ligand amide oxygen [6, 10] .
The distal parts of the R1 side chain, which have been the principle focus of design and modi¢cation of semisynthetic L-lactam antibiotics, also contribute to binding af¢nity. Dissociation constants vary from 700 nM for 7, which bears the penicillin V side chain, to 20 nM for 15, which bears the ceftazidime side chain (Table 1) . By comparison to the acetamido side chain in compound 5 (K i 18 WM), the contribution to a¤nity for each group can be determined. For instance, the ceftazidime side chain contributes 4.0 kcal/mol in di¡erential a¤nity compared to 5. Intriguingly, L-lactam side chains that are associated with inhibitors of AmpC do not necessarily have higher a¤n-ities than boronic acids bearing substrate side chains. For instance, cloxacillin is an inhibitor of AmpC, whereas ceftazidime is a substrate for the enzyme, albeit a poor one ; nevertheless, the ceftazidime analog 15 binds 10-fold better to the enzyme than does the cloxacillin analog 9. Similarly, compound 11, which bears the side chain of the very good substrate cephalothin, binds only two-fold less well than the cloxacillin analog 9.
Although Group I and Group II L-lactamases are mechanistically related, the two enzyme groups have di¡erent substrate preferences and inhibitor pro¢les. To investigate di¡erential recognition between these two classes of L-lactamases, the a¤nity of several of the acylglycineboronic acid inhibitors was determined for the characteristic Group II L-lactamase, TEM-1. Overall, there is a monotonic relationship between the a¤nity of acylglycineboronic acids for AmpC and for TEM-1, with the a¤nities for TEM-1 being 8^40-fold worse. TEM-1, traditionally known as a penicillinase, does not appear to be more selective for R1 side chains associated with penicillins than does the cephalosporinase AmpC for the side chains of R1 side chains associated with cephalosporins (Table 1) . To the extent that Group I and Group II L-lactamases are selective for cephalosporins and penicillins [3] , respectively, this does not seem to owe to di¡erences in the R1 side chains associated with each of these classes of drugs.
The greater a¤nity of the acylglycineboronic acids for AmpC versus TEM-1 suggests that the R1 side chain contributes more to recognition in Group I L-lactamases than it does in Group II L-lactamases. This suggestion is consistent with residue substitution and inhibition studies in these enzymes. Whereas the R1-amide recognition residue Asn132 of Group II L-lactamases can be substituted with an aspartate or a serine with little loss of enzyme activity [22] , the analogous N152D AmpC mutant enzyme loses four orders of magnitude of activity [23] . Also, the C3 (4) carboxylate, on the other side of the L-lactam ring, contributes strongly to recognition of L-lactams by Group II L-lactamases but not to Group I L-lactamases [24] . The importance of this carboxylate for Group II L-lactamases is reinforced by a comparison of the activity against TEM-1 of compound 6 with that of an analogous boronic acid, (1R)-1-phenylacetamido-2-(3-carboxyphenyl)-ethylboronic acid. The latter compound has the same R1 side chain as 6 but also has a carboxylate resembling the C3 carboxylate in penicillins [14] . The carboxylate-containing boronic acid has a K i of 5.9 nM against TEM-1, whereas compound 6 has a K i of 13.8 WM.
Boronic acids mimic the tetrahedral geometry of the transition state of Group I L-lactamases [6, 13, 25] , and it is interesting to compare their placement of the R1 side chains with that of the L-lactam acyl-adduct structures. When we overlap the structure of the AmpC/9 complex with that of a mutant AmpC (Q120L/Y150E) bound to cloxacillin [6] in an acyl-adduct, we observe that the two R1 side chains are placed similarly in both structures (Fig.  7) . The RMSD between the two side chains is 0.9 A î , and most of the interactions are maintained. The greatest positional di¡erences are at the amide nitrogen at the beginning of the R1 side chain, but even here the transitionstate analog and the acyl-adduct maintain the same interactions. On the part of the enzyme, there is little reorganization in the active site region. The RMSD between the CK atoms of conserved residues in the active sites (Ser64, Lys67, residue 150, Asn152, Tyr221, Lys315, and Ala318) of transition-state structure and the acyl-enzyme structure is 0.17 A î (0.44 A î for all atoms of the above residues except residue 150, whose identity di¡ers between the mutant and wild type enzymes). We make two inferences based on this comparison. First, at least for the cloxacillin group, the presence of rest of the L-lactam has little e¡ect on the positioning of the R1 side chain. Second, the similarity of the acyl-adduct ground state to the transition-state analog suggests that progress along the reaction requires little reorganization in the R1 side chain or in the residues with which it interacts. There may be little di¡erential stabilization between the acylated ground state and the transition state in the region of the R1 side chain.
Where the transition-state analog complexes di¡er most from the L-lactam acylated ground-state complexes is in the region of the tetrahedral center. In moving from the planar ester center to the tetrahedral boronic acid, a hydrogen bond is gained between the O2 hydroxyl of the boronic acid and the hydroxyl of Tyr150. The O2, which appears to represent the position of the deacylating water in the high-energy intermediate [13] , hydrogen bonds with Wat402. This water is conserved in native [12] , acyl-enzyme [6] , and transition-state analog structures [13] , and it may identify the region from where the deacylating water attacks the acyl-adduct [6] . The O1 atom of the boronic acid, which represents the position of what was the lactam carbonyl oxygen in the acyl-enzyme intermediate [6] , moves to pick up a hydrogen bond with the backbone oxygen of Ala318 in the tetrahedral adduct. This may be consistent with the status of this oxygen as a hydroxyl in the high-energy intermediate [12, 13] . The overall picture that emerges is that, in moving from an acylated ground state to a transition-state analog complex, structural change is largely localized to the transition from a planar to a tetrahedral center in the ligand itself.
Once very e¡ective, third-generation cephalosporins such as ceftazidime and cefotaxime have become largely useless against hospital pathogens such as E. cloacae because of the hyper-production of Group I L-lactamases. Given the high a¤nity of compounds 10 and 15 in enzyme assays, it seemed worthwhile to investigate their ability to reverse this resistance. Both inhibitors were synergistic when used in combination with the widely used third-generation cephalosporins ceftazidime (Fig. 6 ) and cefotaxime (Table 5) . At high concentrations of 15, the MIC values of these antibiotics were reduced by two orders of magnitude, close to the levels of non-resistant strains. The synergistic e¡ect is perhaps shown most compellingly in the disk diffusion assays (Fig. 6 ). Against non-resistant E. cloacae, compounds 10 and 15 had no obvious e¡ect, whereas against resistant strains of the same bacteria, these compounds showed an unmistakeable synergy. Both inhibitors were also active against an isolate of S. aureus expressing a Group II L-lactamase, although e¤cacies were lower. The ability of 10 and 15 to reverse L-lactamase-based resistance, especially against the nosocomial pathogen E. cloacae, suggests that these compounds may be useful leads for the design of new agents to reverse bacterial resistance to L-lactams.
The X-ray crystal structures of AmpC with 9 and 11 may guide further inhibitor design. In the complex of 9 with AmpC, non-polar complementarity is achieved through interactions with residues Leu119, Leu293, and Ala318. The methyl group of the isoxazole ring of 9 forms van der Waals interactions with the Tyr221. The function of this conserved residue is unknown, but it often forms aromatic polar or stacking interactions with substrates [6] and inhibitors [6, 13] . In both complexes, the R1 side chains only ¢ll part of the enzyme cleft, leaving uncomplemented polar residues such as Asp123, Arg204, and Ser212. Interactions with some of these residues may help explain the increased a¤nity of 15, which is the most polar and the most active of the compounds tested. Intriguingly, Ser212 is just proximal to a site of a tandem insertion in a related Group I L-lactamase that leads to a mutant enzyme resistant to ceftazidime [26] , the L-lactam analog of 15. It may be possible to improve polar complementarity in this series to increase inhibition and speci¢city.
Signi¢cance
Penicillins and cephalosporins have had an enormous impact on human health. Unfortunately, the e¤cacy of these antibiotics is threatened by the emergence of L-lactamases. To understand how L-lactamases recognize L-lactam substrates and L-lactam inhibitors, it would be helpful to know what their binding energies are, but these have been di¤cult to measure because L-lactams form covalent adducts with L-lactamases. The reversible binding of the transition-state analog acylglycineboronic acids allows us to begin to dissect the energetic bases for recognition of the ubiquitous R1 side chains of L-lactam antibiotics by L-lactamases. We observe little relationship between a¤n-ity and whether the R1 side chain derives from a L-lactam substrate or a L-lactam inhibitor of the L-lactamase. Notwithstanding this, some R1 side chains bind tightly to L-lactamases, leading to inhibitors with low K i values for these enzymes. These and related analogs are accessible synthetically and may provide useful tools for studying recognition and mechanism in L-lactamases. Several of the compounds are highly active and selective, and they reverse resistance to L-lactam antibiotics in pathogenic bacteria in cell culture. Coupling interaction energies with structure and synthesis may guide the design of anti-resistance agents in this series.
Materials and methods
Synthesis and analysis
1 H-and 13 C-NMR spectra were recorded on a Brucker DPX- 
Pinacol chloromethaneboronate (1) [27]
Butyl lithium in hexane (2.5 M, 9.2 ml, 23 mmol) was added dropwise to a stirred solution of bromochloromethane (1.5 ml, 23 mmol) and tri-tert-butylborate (2.3 ml, 21 mmol) in anhydrous THF (25 ml) at 378³C under nitrogen £ow; the resulting mixture was allowed to react for 1 h. Thereafter, the reaction was quenched at 378³C with trimethylsilyl chloride (3.2 ml, 25.2 mmol), and the temperature gradually raised to room temperature (RT). After 16 h, a solution of pinacol (2.7 g, 23 mmol) in ethyl ether (10 ml) was added dropwise, and the mixture was stirred for an additional 3 h. The solution was diluted with water (20 ml) and ethyl ether (10 ml), and the aqueous phase was extracted with ethyl ether (3U10 ml). The combined organic phases were washed with brine and dried (MgSO 4 ). After removal of the solvent under reduced pressure, the oily residue was distilled in vacuo (bp 55^56³C/2 mm Hg) to yield 1 (3.08 g, 76%) as a colorless oil. 
Pinacol N,NP-diformamidomethaneboronate (2) [28]
A solution of 1 (836 mg, 4.73 mmol) in anhydrous CH 3 CN (2 ml) was added to a solution of sodium diformylamide (540 mg, 5.68 mmol) in anhydrous CH 3 CN (2 ml) and the mixture stirred for 3 h at 80³C. The white precipitate (NaCl) was centrifuged o¡, the supernatant concentrated, and the residue distilled under reduced pressure to give 2 as a clear dense oil (735 mg, 73%), bp 
Pinacol bis-(trimethylsilyl)-aminomethaneboronate (4)
According to the procedure described [29] , lithium hexamethyldisilazane in THF (1.0 M, 4.6 ml, 4.6 mmol) was added dropwise to a solution of 1 (800 mg, 4.6 mmol) in anhydrous ethyl ether (6 ml) cooled at 378³C under nitrogen. After stirring for 10 min at 378³C, the cooling bath was removed and the solution stirred for 2 h at RT. The precipitate (LiCl) was centrifuged, the supernatant concentrated under reduced pressure, and the oily residue was distilled under reduced pressure (bp 80^81³C/1 mm Hg) to give 4 (780 mg, 57%) as a colorless oil. 
Reaction of pinacol bis-(trimethylsilyl)-aminomethaneboronate (4) with acyl chlorides: general procedure [31]
A solution of anhydrous methanol in THF (1 mmol, 2.5 M) was added at 310³C to a solution of 4 (1 mmol) in THF under nitrogen. The cooling bath was removed, and the reaction mixture was stirred for 1 h at RT. The reaction mixture was once again cooled to 310³C. A solution of the acyl derivative (1 mmol) in THF was slowly added and allowed to react for the reported time whereupon a GLC analysis indicated total disappearance of 4. The solvent was evaporated in vacuo and the residue puri¢ed by crystallization.
Pinacol phenylacetamidomethaneboronate (6)
Phenylacetylchloride was allowed to react with 4 for 1 h. 
Enzyme puri¢cation
AmpC from Escherichia coli was expressed and puri¢ed to homogeneity as described [12] . The TEM-1 gene was ampli¢ed from pBR322 by PCR and expressed from a pAlterEx II plasmid (Promega, Madison, WI, USA) from transformed E. coli JM109 cells. TEM-1 was expressed and puri¢ed using a procedure modi¢ed from Vanhove et al. [32] ; a full description will be published elsewhere.
Enzyme inhibition assays
The pinacol esters of the acylglycineboronic acids were hydrolyzed to the free acids by dissolving them in 50 mM phosphate bu¡er at pH 7.0 [33] at a concentration of 10 mM; more dilute stocks (1 mM to 100 WM) were subsequently prepared as necessary. Kinetic measurements with AmpC were performed using cephalothin as a substrate [11] . Reactions were initiated by the addition of 1.5 nM enzyme. No incubation e¡ect was detected for any compound, consistent with earlier studies [11, 25] . IC 50 values were determined at 100 WM substrate concentration.
TEM-1 enzyme assays used 100 WM furylacryloylamidopenicillanic acid as substrate, monitoring absorbance changes at 340 nm on an HP8453 spectrophotometer. Reactions were initiated with addition of 0.3 nM enzyme, using the same bu¡er as in the AmpC assays.
The K i values for compounds 3^14 were obtained by comparison of progress curves in the presence and absence of inhibitor [25] . Su¤cient inhibitor was used to give at least 50% inhibition. This method correlates well with full K i analysis through coupled substrate and inhibitor concentration variation [11] . For compound 9, a K i of 170 þ 10 nM, consistent with the value of 160 nM determined by progress curve analysis, was also determined by Lineweaver^Burk analysis of multiple substrate and inhibitor concentrations (data not shown).
The selectivity of compounds 3 and 15 for L-lactamases was determined by measuring their activity against K-chymotrypsin (bovine pancreatic), L-trypsin (bovine pancreatic), and elastase (porcine pancreatic), all from Sigma (St. Louis, MO, USA). Substrates for K-chymotrypsin (N-benzoyl-L-tyrosine ethyl ester, BTEE) and L-trypsin (N-benzoyl-L-arginine ethyl ester, BAEE) were also purchased from Sigma. The elastase substrate used (elastase substrate 1, MeOSuc-Ala-Ala-Pro-Val-pNA) was purchased from Calbiochem (San Diego, CA, USA). Substrates were diluted from 10 mM DMSO stock solutions, and all reactions were performed in 50 mM potassium phosphate bu¡er, pH 7.0, 25³C. For K-chymotrypsin, 140 WM of BTEE was used, the reactions were initiated by addition of 5 Wl of a 0.1 mg/ml enzyme stock solution, and monitored at 260 nm. For L-trypsin, 200 WM of BAEE was used, the reactions were initiated by the addition of 5 Wl of a 0.2 mg/ml enzyme stock solution, and monitored at 260 nm. For elastase, 640 WM of elastase substrate was used, the reactions were initiated by the addition of 30 Wl of a 0.2 mg/ml enzyme stock solution, and monitored at 385 nm. Initial rate ¢ts to the absorbance data for the ¢rst 150 s of each reaction were used to determine reaction velocities.
Crystal growth and structure determination
Co-crystals of 9 and 11 were grown by vapor di¡usion in hanging drops equilibrated over 1.7 M potassium phosphate bu¡-er (pH 8.7) using microseeding techniques. The initial concentration of protein in the drop was 95 WM, and the concentrations of each inhibitor were 586 WM. The inhibitors were added to the crystallization drop in a 2% DMSO, 1.7 M potassium phosphate bu¡er (pH 8.7) solution. Crystals appeared within 3^5 days after equilibration at 23³C.
Data were collected on the DND-CAT beam line (5IDB) of the Advanced Photon Source at Argonne National Lab at 100 K using a 162 mm Mar CCD detector. Prior to data collection, crystals were immersed in a cryoprotectant solution of 20% sucrose, 1.7 M potassium phosphate, pH 8.7, for about 20 s, then £ash-cooled in liquid nitrogen. Each data set was measured from a single crystal.
Re£ections were indexed, integrated, and scaled using the HKL program suite [34] (Table 3 ). The space group was C2, with two AmpC molecules in the asymmetric unit. Each AmpC molecule contained 358 residues. The structure was determined by molecular replacement using an AmpC/boronic acid complexed structure [13] , with inhibitor and water molecules removed, as the initial phasing model. The model was re¢ned using the maximum likelihood target in CNS and included a bulk solvent correction [35] . Sigma A-weighted electron density maps were calculated using CNS, and manual rebuilding was done in the program O [36] . The inhibitor was built into the observed di¡erence density in each active site of the asymmetric unit, and the structure of the complex was further re¢ned using CNS (Table 3 ). All atoms of inhibitor 9 were re¢ned with an occupancy of 1.0. All atoms of inhibitor 11 were re¢ned with an occupancy of 1.0, except for atoms of the thiophene ring (C9, C10, C11 and S1) which were re¢ned with an occupancy of 0.5 for each of the two possible conformations.
Microbiology
Compounds 10 and 15 were tested for synergy with L-lactams against pathogenic bacteria that are sensitive to L-lactams and to pathogenic bacteria that are resistant to L-lactams through production of either Group I or Group II L-lactamases. Bacterial strains tested included: E. cloacae EB5 (L-lactamase negative), E. cloacae 265A (Group I L-lactamase hyper-producer), and S. aureus V41 (Group II L-lactamase producer). MIC values were determined with Mueller^Hinton Broth II using the microdilution method according to NCCLS guidelines [37] . The L-lactams cefotaxime and ceftazidime were used with E. cloacae, and amoxicillin was used with S. aureus. Checkerboard assays were performed to study the synergistic e¡ects.
Disk di¡usion plate assays were performed as follows. E. cloacae EB5 and E. cloacae 265A were each grown to log-phase and then diluted in TY broth to a turbidity equivalent to McFarland 1. The cultures were further diluted 100-fold into melted TY agar medium and allowed to solidify in Falcon 150U25 mm plates. The plates were then spotted with ceftazidime (25 Wg per disk for the EB5 plate and 50 Wg per disk for the 265A plate; upper disks) and 100 Wg of 15 (lower disks on the left) and 100 Wg of 10 (lower disks on the right). After overnight incubation at 35 ³C, the zones of inhibition were imaged.
